Source: CentralCharts

Press Release: Soligenix : Soligenix Receives US Patent for Dusquetide Related Analogs

Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that the US Patent Office will issue the patent titled "Novel Peptides for Treating and Preventing Immune-Related Disorders, Including Treating and Preventing Infection by Modulating Innate Immunity" on April 9, 2019.

Read full article »

Top Competitors or Alternatives

Missing a competitor? Contribute!

Annual Revenue
Employees
Christopher J. Schaber's photo - President & CEO of Soligenix

President & CEO

Christopher J. Schaber

CEO Approval Rating

68/100

Soligenix develops and commercializes biotherapeutics for the treatment of gastrointestinal disorders, inflammation and oncology diseases. Read more